Clinical trial
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
NCT00315211 · Aultman Health Foundation, Other · Terminated
Key facts
| NCT number | NCT00315211 |
|---|---|
| Title | Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer |
| Official title | Phase 2 Study of Weekly Topotecan With Docetaxel for Recurrent Small Cell Lung Cancer |
| Lead sponsor | Aultman Health Foundation, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mediastinal Neoplasms |
| Intervention type | Drug |
| Interventions | Intravenous Topotecan, Intravenous Docetaxel |
| Enrollment | 7 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Nov 8, 2007 |
| First posted | Apr 18, 2006 |
| Last update posted | Aug 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: